Price Chart

Executive Summary

Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), widened from $18.8M ($0.25/share) in H1 2025, driven by a $42.2M non-cash remeasurement of warrant liabilities as the stock price rose above the $11.50 strike. Operating loss increased 42.9% to $27.1M on higher R&D spend ($20.9M vs $14.2M). The company ended Q2 with $104.8M in cash/short-term deposits, up from $76.9M at year-end 2025, boosted by a $20M equity investment from Tolmar at a 25% premium and $15M upfront payment under the Tolmar collaboration for U.S. prostate cancer commercialization. Key clinical catalysts include completed enrollment in the pivotal ReSTART trial (top-line data late 2026/early 2027), promising REGAIN glioblastoma interim data, and a 100% objective response rate in a head & neck combo study with pembrolizumab. The Tolmar deal provides up to $161.5M in milestones plus 60% of net sales on supply, validating the platform but also capping U.S. prostate cancer upside for Alpha Tau.

Key Facts

• Net loss widened to $68.8M in H1 2026 from $18.8M in H1 2025, largely due to $42.2M non-cash warrant remeasurement.
• Cash, cash equivalents, short-term deposits and restricted deposits totaled $104.8M as of June 30, 2026, up from $76.9M at Dec 31, 2025.
• Tolmar collaboration: $20M equity investment at $11.99/share (25% premium to 30-day VWAP) + $15M for manufacturing capacity + up to $161.5M in milestones + 60% of net sales on supply.
• Completed enrollment in U.S. pivotal ReSTART trial (88 patients) for recurrent cSCC; top-line data expected late 2026 or early 2027.
• REGAIN glioblastoma trial: 100% local disease control, 67% complete response rate in first 3 patients; FDA cleared full enrollment.
• Head & neck combo study with pembrolizumab: 100% objective response rate (4 CR, 5 PR) and 18.2-month median OS vs 12.3-month historical benchmark.
• R&D expenses rose 47.2% to $20.9M, driven by increased clinical trial activity, raw materials, and employee costs.
• Operating loss increased 42.9% to $27.1M; total operating expenses were $27.1M vs $19.0M in H1 2025.
• Accumulated deficit reached $258.9M as of June 30, 2026.
• Company believes existing capital resources adequate to fund operations for at least two years.

Financial Impact

Net loss of $68.8M in H1 2026, driven by $42.2M non-cash warrant remeasurement. Cash position strengthened to $104.8M. Tolmar deal provides $35M upfront ($20M equity + $15M manufacturing) plus up to $161.5M in milestones and 60% of net sales on supply.

Risk Factors

• ReSTART trial top-line data may miss efficacy or safety thresholds, delaying or preventing PMA submission.
• Tolmar collaboration caps U.S. prostate cancer upside at 60% of net sales; Alpha Tau retains no direct commercialization economics for this indication.
• Clinical-stage company with no product revenue; continued reliance on equity/debt financing or partnership milestones to fund operations beyond current 2-year runway.
• Warrant liability ($47.5M) creates balance sheet volatility; further stock price appreciation would increase non-cash losses.
• Competition from established radiation therapies and emerging modalities (e.g., targeted alpha therapy, proton therapy) may limit commercial adoption.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

US Market Status

Related Tickers